SCHEMBL232126

SCHEMBL232126

N=CCN[C@@H](CCCN)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.42
GGT1 P19440 1/20 0.41
CPB2 Q96IY4 4/20 0.39
GSR P00390 1/20 0.37
SLC6A5 Q9Y345 1/20 0.37
RNPEP Q9H4A4 1/20 0.36
MMP2 P08253 1/20 0.35
MMP9 P14780 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
GNPAT O15228 1/20 0.33
CTH P32929 1/20 0.33
LMNA P02545 1/20 0.32
TLR2 O60603 1/20 0.32
GABRR1 P24046 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3433410 1.00 FOLH1 (0.42) FOLH1GGT1CPB2GSRSLC6A5
SCHEMBL27799398 1.00 FOLH1 (0.42) FOLH1GGT1CPB2GSRSLC6A5
Hydrochloric Acid SCHEMBL15923983 0.98 FOLH1 (0.41) FOLH1GGT1CPB2GSRSLC6A5
SCHEMBL45766 0.95 FOLH1 (0.49) FOLH1GGT1CPB2GSRSLC6A5
SCHEMBL6676701 0.95 FOLH1 (0.49) FOLH1GGT1CPB2GSRSLC6A5
Hydrochloric Acid SCHEMBL15923088 0.93 FOLH1 (0.47) FOLH1GGT1CPB2GSRSLC6A5
Acetic Acid SCHEMBL268741 0.90 FOLH1 (0.45) FOLH1GGT1CPB2GSRSLC6A5
SCHEMBL8843334 0.85 MMP2 (0.41) GGT1CPB2MMP2MMP9CA1
SCHEMBL1062835 0.82 FOLH1 (0.42) FOLH1GGT1CPB2GSRSLC6A5
SCHEMBL20586820 0.82 FOLH1 (0.42) FOLH1GGT1CPB2GSRSLC6A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 518 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230309521-A1 NOVEL METHOD FOR PREPARING ANIMAL MODEL OF CEREBROVASCULAR DISEASE AND METHOD FOR PRODUCING ANIMAL HAVING SMALL INDIVIDUAL DIFFERENCE IN SUSCEPTIBILITY TO CEREBROVASCULAR DISEASE ONSET BY USING ANIMAL MODEL FOR CEREBROVASCULAR DISEASE PREPARED THEREBY DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2023-10-05 US claimed
EP-4197323-A1 NOVEL METHOD FOR PREPARING ANIMAL MODEL OF CEREBROVASCULAR DISEASE AND METHOD FOR PRODUCING ANIMAL HAVING SMALL INDIVIDUAL DIFFERENCE IN SUSCEPTIBILITY TO CEREBROVASCULAR DISEASE ONSET BY USING ANIMAL MODEL FOR CEREBROVASCULAR DISEASE PREPARED THEREBY Dongguk University Industry-Academic Cooperation Foundation (KR) 2023-06-21 EP claimed
US-20130130263-A1 GAMETES SEPARATION METHODS, COMPOSITIONS AND USES THEREOF ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) 2013-05-23 US claimed
EP-2539434-A1 GAMETES SEPARATION METHODS, COMPOSITIONS AND USES THEREOF Assistance Publique - Hôpitaux de Paris (FR) 2013-01-02 EP claimed
WO-2011104336-A1 GAMETES SEPARATION METHODS, COMPOSITIONS AND USES THEREOF ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (FR) 2011-09-01 WO claimed
EP-2361967-A1 Gametes separation methods, compositions and uses thereof Assistance Publique - Hôpitaux de Paris (FR) 2011-08-31 EP claimed
JP-4579349-B2 2010-11-10 JP claimed
WO-2005105065-A2 THIAZOLE-BASED NITRIC OXIDE DONORS FOR TREATING INFLAMMATORY BOWEL DISEASES RENOPHARM LTD. (IL) 2005-11-10 WO claimed
WO-2005046660-A1 MODULATING SUBSTANCES OF THE NITRIC OXID (NO) - CYCLIC GUANOSINE - 3’,5’- MONOPHOSPHATE (cGMP) SIGNALING PATHWAY FOR THE TREATMENT OF DENTAL DISORDERS CELL CENTER COLOGNE GMBH (DE) 2005-05-26 WO claimed
US-20040162269-A1 Composition and method of treating arthritis PETRUS EDWARD J (US) 2004-08-19 US claimed
WO-1996002241-A9 USE OF NITROGEN OXIDE SPECIES AND ADDUCTS TO INHIBIT SKELETAL MUSCLE CONTRACTION 1996-02-29 WO claimed
WO-1996002268-A1 INHIBITION OF VIRUS BY NITRIC OXIDE BRIGHAM AND WOMEN'S HOSPITAL (US) 1996-02-01 WO claimed
WO-1996002241-A1 USE OF NITROGEN OXIDE SPECIES AND ADDUCTS TO INHIBIT SKELETAL MUSCLE CONTRACTION DUKE UNIVERSITY (US) 1996-02-01 WO claimed
US-5449688-A Nitric oxide synthase inhibitor or scavenger THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1995-09-12 US claimed
EP-0603335-A4 ATTENUATION OF THE OPIOID WITHDRAWAL SYNDROME BY INHIBITORS OF NITRIC OXIDE SYNTHASE. US HEALTH (US) 1995-07-05 EP claimed
WO-1995014465-A2 METHODS FOR AMELIORATION OF IMMUNODEFICIENCY VIRUS INDUCED NEURODEGENERATION BY COVERING NITRIC OXIDE OR SUPEROXIDE CONCENTRATION THE JOHNS HOPKINS UNIVERSITY (US) 1995-06-01 WO claimed
WO-1995013805-A1 USE OF NITRIC OXIDE SYNTHASE INHIBITORS IN THE TREATMENT OF AUTOIMMUNE DISEASES DUKE UNIVERSITY MEDICAL CENTER (US) 1995-05-26 WO claimed
EP-0603335-A1 ATTENUATION OF THE OPIOID WITHDRAWAL SYNDROME BY INHIBITORS OF NITRIC OXIDE SYNTHASE THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1994-06-29 EP claimed
US-5225440-A ATTENUATION OF THE OPIOID WITHDRAWAL SYNDROME BY INHIBITORS OF NITRIC OXIDE SYNTHASE THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1993-07-06 US claimed
WO-1993005775-A1 ATTENUATION OF THE OPIOID WITHDRAWAL SYNDROME BY INHIBITORS OF NITRIC OXIDE SYNTHASE THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1993-04-01 WO claimed